

Trident Ltd: Q3FY18 Result Update

Headwinds Persist

We had expected a 5-7% topline growth in FY18 alongwith slight margin improvement (expected to be backended in H2FY18). However Q3FY18 was also subdued in line with H1FY18 as the textile sector continues to be hit by mulitple headwinds such as higher cotton prices, appreicating rupee, lower government incentives and uneven vendor procurement cycle on account of de-stocking in terry towels. Sales at INR 1137cr grew 1% y-o-y and slightly below estimates of a 4% y-o-y growth in revenues. EBITDA at INR 200cr de-grew by 11% from INR 225 Cr in Q3FY17 and this was below our estimates of a 7% de-growth. EBITDA margin at 17.6% in Q3FY18 were 250 bps lower than Q3FY17 margins and slightly below our estimates of 18% margins. Reported PAT of INR 73 Cr was 7% lower than Q3FY17 PAT of INR 79 Cr on account of higher tax expense. Therefore while the home textile industry continues to face headwinds (especially terry towels), paper continues to outperform. We have cut our margin expectation for FY18E and FY19E while retaining our topline growth expectation. Undemanding valuation provide margin of safety and we re-iterate "BUY" with a revised price target of INR 110 (earlier 118) as we roll forward to FY20E.

Muted performance from home textiles; Recovery delayed

Home Textiles revenues grew 3% in this quarter from INR 920 Cr in Q3FY17 to INR 945 Cr in Q3FY18 led by higher utilization in bed sheets which increased from 29% in FY17 to 42% in 9MFY18 (our full year estimate is 44% and Trident should surpass that). Terry towel utilization fell further in this quarter from 50% in FY17 to 45% in 9MFY18 due to high base and uneven vendor procurement cycle. However domestic home textile business continues its healthy growth. Adjusting other income, margins slightly improved but are still lower on a 9M basis with 9MFY18 margins at 14.6% as against 17.7% margins in 9MFY17. This was due to lower utilization in terry towel along with high prices for good quality cotton and inspite of manpower rationalization undertaken by the company. Yarn utilization increased further to 95% with lower captive consumption leading to higher yarn sales which also impacted margins negatively.

Paper continues to outperform; Debt repayment on track

Paper utilization was maintained at 89% in Q3FY18 and revenues are almost flat on a y-o-y basis for the 9M period. However cheaper raw material and stronger realizations have led to margins improving from 37% in Q3FY17 to 39% in Q3FY18. On a 9M basis, margins have improved from 34% in 9MFY17 to 43% in 9MFY18. Copier sales were softer in Q3FY18 at 48% vs. 52% in Q2FY18 which led to lower paper margins than the previous quarter. Company has repaid debt of INR 466 Cr in 9MFY18 and thus long term debt stands at INR INR 1,660 Cr. This debt repayment has helped reduced interest outgo.

Outlook and valuations: Positive; Re-iterate BUY

While top line growth will be muted due to higher captive yarn consumption, the bottom line can catapult 30% over FY18-20E as financial leverage plays out. At an inexpensive valuation of 8x FY20E P/E, and the ability to generate free cash flows in excess of INR600cr every year provides a margin of safety. We value Trident at 11x FY20E P/E and re-iterate our Buy rating.

Year to March	Q3FY18	Q3FY17	% change	Q2FY18	% change	FY17	FY18E	FY19E
Net sales (INR cr)	1137	1122.34	1%	1155	-2%	4,694	4,827	5,372
Growth (%)						27	3	11
EBITDA (INR cr)	200	225	-11%	174	15%	888	828	943
Adj PAT (INR cr)	73	79	-7%	51	43%	334	305	403
Growth (%)						47	-9	32
Dil. EPS (INR)						6.6	6.0	7.9
Diluted P/E (x)						12.1	13.3	10.1
EV/EBITDA (x)						7.6	7.4	6.0
ROAE (%)						15.5	10.8	13.0

CMP INR: 79 Rating: BUY Target Price INR: 110 Upside: 39%

Kshitij Kaji Research Analyst ksjitij.kaji@edelweissfin.com

Bloomberg:	TRID:IN
52-week range (INR):	110/67
Share in issue (cr):	5.1
M cap (INR cr):	4,000
Avg. Daily Vol. BSE/NSE :('000):	200
Promoter Holding (%)	67.77

Date: 31st January 2018

Q3FY18 Result Highlights

Particulars	Q3FY18	Q3FY17	% change	Q2FY18	% change	FY17	FY18E	FY19E
Income from operations	1137	1122	1%	1155	-2%	4,694	4,827	5,372
Cost of goods sold	593	534	11%	614	-3%	2,673	2,848	3,148
Employee expenses	109	145	-25%	136	-20%	579	596	663
Other expenses	235	219	8%	231	2%	1,133	1,151	1,281
Total operating expenses	937	897	4%	981	-4%	3,806	3,999	4,428
EBITDA	200	225	-11%	174	15%	888	828	943
Depreciation and amortization	101	104	-2%	102	-1%	413	413	421
EBIT	99	122	-19%	72	38%	476	415	522
Interest expenses	25	30	-17%	32	-22%	141	118	98
Other income	31	11	191%	36	-14%	104	100	100
PBT	105	102	3%	76	38%	439	397	525
Provision for tax	32	24	36%	25	28%	102	92	122
Core profit	73	79	-7%	51	43%	337	305	403
Extraordinary items	0	0	NA	0	NA	0	0	0
Adjusted net profit	73	79	-7%	51	43%	337	305	403
No. of shares (Cr)						51	51	51
Diluted EPS (INR)						6.6	6.0	7.9

Trident Ltd.

Financials

i manciais					
Income statement					(INR Cr)
Year to March	FY16	FY17	FY18E	FY19E	FY20E
Income from operations	3,684	4,694	4,827	5,372	5,917
Direct costs	2,058	2,673	2,848	3,148	3,455
Employee costs	434	579	596	663	730
Other expenses	907	1,133	1,151	1,281	1,399
Total operating expenses	2,965	3,806	3,999	4,428	4,854
EBITDA	719	888	828	943	1,063
Depreciation and amortisatic	338	413	413	421	429
EBIT	381	476	415	522	634
Interest expenses	136	141	118	98	79
Other income	32	104	100	100	100
Profit before tax	277	439	397	525	654
Provision for tax	49	102	92	122	152
Core profit	228	337	305	403	503
Extraordinary items	-0	-3	0	0	0
Profit after tax	227	334	305	403	503
Minority Interest	1	0	0	0	0
Share from associates	0	0	0	0	0
Adjusted net profit	229	334	305	403	503
Equity shares outstanding (mr	51	51	51	51	51
EPS (INR) basic	4.5	6.6	6.0	7.9	9.9
Diluted shares (Cr)	50.9	50.9	50.9	50.9	50.9
EPS (INR) fully diluted	4.5	6.6	6.0	7.9	9.9
Dividend per share	0.9	1.2	1.3	1.7	2.1
Dividend payout (%)	19.8	18.1	21.0	21.0	21.0
Equity shares outstanding (mr EPS (INR) basic Diluted shares (Cr) EPS (INR) fully diluted Dividend per share	51 4.5 50.9 4.5 0.9	51 6.6 50.9 6.6 1.2	51 6.0 50.9 6.0 1.3	51 7.9 50.9 7.9 1.7	51 9.9 50.9 9.9 2.1

Year to March	FY16	FY17	FY18E	FY19E	FY20E
Operating expenses	80.5	81.1	82.8	82.4	82.0
Depreciation	9.2	8.8	8.5	7.8	7.2
Interest expenditure	3.7	3.0	2.4	1.8	1.3
EBITDA margins	19.5	18.9	17.2	17.6	18.0
Net profit margins	6.2	7.1	6.3	7.5	8.5

Growth metrics (%)					
Year to March	FY16	FY17	FY18E	FY19E	FY20E
Revenues	(1.9)	27.4	2.8	11.3	10.2
EBITDA	8.8	23.5	(6.8)	13.9	12.7
PBT	64.7	58.7	(9.4)	32.0	24.7
Net profit	93.4	47.9	(8.6)	32.0	24.7
EPS	94.2	47.2	(9.4)	32.0	24.7

Ratios					
Year to March	FY16	FY17	FY18E	FY19E	FY20E
ROAE (%)	14.7	15.5	10.8	13.0	14.6
ROACE (%)	8.1	8.6	7.4	9.5	11.7
Debtors (days)	18	29	22	22	22
Current ratio	4.4	4.7	5.1	5.3	5.7
Debt/Equity	2.0	1.0	0.8	0.6	0.4
Inventory (days)	90	60	70	70	70
Payable (days)	31	24	25	25	25
Cash conversion cycle (days)	77	65	67	67	67
Debt/EBITDA	4.7	3.2	2.8	2.1	1.5
Adjusted debt/Equity	1.9	1.0	0.7	0.5	0.3

Valuation parameters

Year to March	FY16	FY17	FY18E	FY19E	FY20E
Diluted EPS (INR)	4.5	6.6	6.0	7.9	9.9
Y-o-Y growth (%)	94.2	47.2	(9.4)	32.0	24.7
CEPS (INR)	11.1	14.7	14.1	16.2	18.3
Diluted P/E (x)	17.8	12.1	13.3	10.1	8.1
Price/BV(x)	2.4	1.5	1.4	1.2	1.1
EV/Sales (x)	2.0	1.4	1.3	1.0	0.9
EV/EBITDA (x)	10.2	7.6	7.4	6.0	4.7
Diluted shares O/S	50.9	50.9	50.9	50.9	50.9
Basic EPS	4.5	6.6	6.0	7.9	9.9
Basic PE (x)	17.8	12.1	13.3	10.1	8.1
Dividend yield (%)	1.1	1.5	1.4	1.8	2.2

As on 31st March	FY16	FY17E	FY18E	FY19E	FY20E
Equity share capital	449	449	449	449	449
Preference Share Capital	60	60	60	60	60
Reserves & surplus	1,210	2,247	2,488	2,807	3,204
Shareholders funds	1,719	2,696	2,937	3,256	3,653
Secured loans	3,368	2,852	0	0	C
Unsecured loans	0	0	0	0	C
Borrowings	3,368	2,852	2,352	1,952	1,552
Minority interest	0	0	0	0	C
Sources of funds	5,147	5,608	5,349	5,268	5,265
Gross block	6,163	5,109	5,209	5,309	5,409
Depreciation	2,333	764	1,176	1,597	2,028
Net block	3,830	4,345	4,032	3,711	3,383
Capital work in progress	62	123	0	0	(
Total fixed assets	3,892	4,468	4,032	3,711	3,383
Unrealised profit	0	0	0	0	(
Investments	94	105	100	100	100
Inventories	909	775	926	1,030	1,135
Sundry debtors	177	375	291	324	357
Cash and equivalents	82	133	276	390	590
Loans and advances	320	222	228	254	280
Other current assets	0	0	0	0	(
Total current assets	1,487	1,505	1,721	1,998	2,362
Sundry creditors and others	312	310	331	368	403
Provisions	24	8	8	8	9
Total CL & provisions	336	318	339	376	414
Net current assets	1,152	1,187	1,383	1,622	1,948
Net Deferred tax	-173	-166	-166	-166	-166
Misc expenditure	182	14	0	0	(
Uses of funds	5,147	5,609	5,349	5,268	5,265
Book value per share (INR)	34	54	59	65	73

Cash flow statement					(INR cr)
Year to March	FY16	FY17E	FY18E	FY19E	FY20E
Net profit	228	340	305	403	503
Add: Depreciation	338	413	413	421	429
Add: Misc expenses written	-50	169	14	0	0
Add: Deferred tax	48	-7	0	0	0
Add: Others	1	0	0	0	0
Gross cash flow	566	914	732	824	932
Less: Changes in W. C.	176	-16	52	125	125
Operating cash flow	389	930	680	699	806
Less: Capex	1,144	989	-23	100	100
Free cash flow	-754	-59	703	599	706


Edelweiss Broking Limited, 1st Floor, Tower 3, Wing B, Kohinoor City Mall, Kohinoor City, Kirol Road, Kurla(W) Board: (91-22) 4272 2200

Vinay Khattar

Head Research

vinay.khattar@edelweissfin.com

Rating	Expected to
Buy	appreciate more than 15% over a 12-month period
Hold	appreciate between 5-15% over a 12-month period
Reduce	Return below 5% over a 12-month period



Disclaimer

Edelweiss Broking Limited ("EBL" or "Research Entity") is regulated by the Securities and Exchange Board of India ("SEBI") and is licensed to carry on the business of broking, depository services and related activities. The business of EBL and its Associates (list available on www.edelweissfin.com) are organized around five broad business groups – Credit including Housing and SME Finance, Commodities, Financial Markets, Asset Management and Life Insurance.

Broking services offered by Edelweiss Broking Limited under SEBI Registration No.: INZ000005231; Name of the Compliance Officer: Mr. Brijmohan Bohra, Email ID: complianceofficer.ebl@edelweissfin.com Corporate Office: Edelweiss House, Off CST Road, Kalina, Mumbai - 400098; Tel. 18001023335/022-42722200/022-40094279

This Report has been prepared by Edelweiss Broking Limited in the capacity of a Research Analyst having SEBI Registration No.INH00000172 and distributed as per SEBI (Research Analysts) Regulations 2014. This report does not constitute an offer or solicitation for the purchase or sale of any financial instrument or as an official confirmation of any transaction. The information contained herein is from publicly available data or other sources believed to be reliable. This report is provided for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. The user assumes the entire risk of any use made of this information. Each recipient of this report should make such investigation as it deems necessary to arrive at an independent evaluation of an investment. The investment discussed or views expressed may not be suitable for all investors.

This information is strictly confidential and is being furnished to you solely for your information. This information should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject EBL and associates / group companies to any registration or licensing requirements within such jurisdiction. The distribution of this report in certain jurisdictions may be restricted by law, and persons in whose possesion this report comes, should observe, any such restrictions. The information given in this report is as of the date of this report and there can be no assurance that future results or events will be consistent with this information. This information is subject to change without any prior notice. EBL reserves the right to make modifications and alterations to this statement as may be required from time to time. EBL or any of its associates / group companies shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. EBL is committed to providing independent and transparent recommendation to its clients. Neither EBL nor any of its associates, group companies, directors, employees, agents or representatives shall be liable for any damages whether direct, indirect, special or consequential including loss of revenue or lost profits that may arise from or in connection with the use of the information. Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein. Past performance is not necessarily a guide to future performance. The disc

EBL shall not be liable for any delay or any other interruption which may occur in presenting the data due to any reason including network (Internet) reasons or snags in the system, break down of the system or any other equipment, server breakdown, maintenance shutdown, breakdown of communication services or inability of the EBL to present the data. In no event shall EBL be liable for any damages, including without limitation direct or indirect, special, incidental, or consequential damages, losses or expenses arising in connection with the data presented by the EBL through this report.

We offer our research services to clients as well as our prospects. Though this report is disseminated to all the customers simultaneously, not all customers may receive this report at the same time. We will not treat recipients as customers by virtue of their receiving this report.

EBL and its associates, officer, directors, and employees, research analyst (including relatives) worldwide may: (a) from time to time, have long or short positions in, and buy or sell the securities thereof, of company(ies), mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the subject company/centry discussed herein or act as advisor or lender/borrower to such company(ies) or have other potential/material conflict of interest with respect to any recommendation and related information and opinions at the time of publication of research report or at the time of public appearance. EBL may have proprietary long/short position in the above mentioned scrip(s) and therefore should be considered as interested. The views provided herein are general in nature and do not consider risk appetite or investment objective of any particular investor; readers are requested to take independent professional advice before investing. This should not be construed as invitation or solicitation to do business with EBL.

EBL or its associates may have received compensation from the subject company in the past 12 months. EBL or its associates may have received compensation for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. EBL or its associates may have received any compensation for investment banking or merchant banking or merchant banking or brokerage services from the subject company in the past 12 months. EBL or its associates may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. EBL or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report. Research analyst or his/her relative or EBL's associates may have financial interest in the subject company. EBL, its associates, research analyst and his/her relative may have other potential/material conflict of interest with respect to any recommendation and related information and opinions at the time of publication of research

Participants in foreign exchange transactions may incur risks arising from several factors, including the following: (i) exchange rates can be volatile and are subject to large fluctuations; (ii) the value of currencies may be affected by numerous market factors, including world and national economic, political and regulatory events, events in equity and debt markets and changes in interest rates; and (iii) currencies may be subject to devaluation or government imposed exchange controls which could affect the value of the currency. Investors in securities such as ADRs and Currency Derivatives, whose values are affected by the currency of an underlying security, effectively assume currency risk.

Research analyst has served as an officer, director or employee of subject Company: No EBL has financial interest in the subject companies: No

EBL's Associates may have actual / beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of research report.

Research analyst or his/her relative has actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of research report: No

EBL has actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of research report. No Subject company may have been client during twelve months preceding the date of distribution of the research report.

There were no instances of non-compliance by EBL on any matter related to the capital markets, resulting in significant and material disciplinary action during the last three years. A graph of daily closing prices of the securities is also available at www.nseindia.com

Analyst Certification:

The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Additional Disclaimer for U.S. Persons

Edelweiss is not a registered broker – dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition Edelweiss is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act") and under with the 1934 Act, the "Acts), and under

Disclaimer

applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by Edelweiss, including the products and services described herein are not available to or intended for U.S. persons.

This report does not constitute an offer or invitation to purchase or subscribe for any securities or solicitation of any investments or investment services and/or shall not be considered as an advertisement tool. "U.S. Persons" are generally defined as a natural person, residing in the United States or any entity organized or incorporated under the laws of the United States. US Citizens living abroad may also be deemed "US Persons" under certain rules.

Transactions in securities discussed in this research report should be effected through Edelweiss Financial Services Inc.

Additional Disclaimer for U.K. Persons

The contents of this research report have not been approved by an authorised person within the meaning of the Financial Services and Markets Act 2000 ("FSMA"). In the United Kingdom, this research report is being distributed only to and is directed only at (a) persons who have professional experience in matters relating to investments falling within Article 19(5) of the FSMA (Financial Promotion) Order 2005 (the "Order"); (b) persons falling within Article 49(2)(a) to (d) of the Order (including high net worth companies and unincorporated associations); and (c) any other persons to whom it may otherwise lawfully be communicated (all such persons together being referred to as "relevant persons").

This research report must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this research report relates is available only to relevant persons and will be engaged in only with relevant persons. Any person who is not a relevant person should not act or rely on this research report or any of its contents. This research report must not be distributed, published, reproduced or disclosed (in whole or in part) by recipients to any other person.

Additional Disclaimer for Canadian Persons

Edelweiss is not a registered adviser or dealer under applicable Canadian securities laws nor has it obtained an exemption from the adviser and/or dealer registration requirements under such law. Accordingly, any brokerage and investment services provided by Edelweiss, including the products and services described herein, are not available to or intended for Canadian persons.

This research report and its respective contents do not constitute an offer or invitation to purchase or subscribe for any securities or solicitation of any investments or investment services.

Disclosures under the provisions of SEBI (Research Analysts) Regulations 2014 (Regulations)

Edelweiss Broking Limited ("EBL" or "Research Entity") is regulated by the Securities and Exchange Board of India ("SEBI") and is licensed to carry on the business of broking, depository services and related activities. The business of EBL and its associates are organized around five broad business groups – Credit including Housing and SME Finance, Commodities, Financial Markets, Asset Management and Life Insurance. There were no instances of non-compliance by EBL on any matter related to the capital markets, resulting in significant and material disciplinary action during the last three years. This research report has been prepared and distributed by Edelweiss Broking Limited ("Edelweiss") in the capacity of a Research Analysta sper Regulation 22(1) of SEBI (Research Analysts) Regulations 2014 having SEBI Registration No.INH000000172.